EUVIMEDEUVIMED entdecken
Crossref

Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities

Ilya Golovaty iD, Scott Hagan iD

New England Journal of Medicine · 22.02.2024 · 390 (8) · 677-680

DOI: 10.1056/nejmp2312816 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 22.02.2024. Verfasst von Ilya Golovaty und 1 weiteren Autor:innen. Beteiligte Einrichtung: From the VA Puget Sound Health Care System (I.G., S.H.), and the Division of General Internal Medicine, University of Washington (I.G., S.H.) - both …. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • From the VA Puget Sound Health Care System (I.G., S.H.), and the Division of General Internal Medicine, University of Washington (I.G., S.H.) - both in Seattle.

ORCID-Profile: Ilya Golovaty, Scott Hagan

Zitieren

APA

Golovaty, I., & Hagan, S. (2024). Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities. New England Journal of Medicine, 390(8), 677-680. https://doi.org/10.1056/nejmp2312816

Vancouver

Golovaty I, Hagan S. Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities. New England Journal of Medicine. 2024;390(8):677-680. doi:10.1056/nejmp2312816

BibTeX
@article{Golovaty2024,
  author = {Golovaty, Ilya and Hagan, Scott},
  title = {Direct-to-Consumer Platforms for New Antiobesity Medications — Concerns and Potential Opportunities},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {8},
  pages = {677--680},
  doi = {10.1056/nejmp2312816}
}
Kostenlos starten →